Open

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

Federal funding opportunity PAR-25-069 from National Institutes of Health (Department of Health and Human Services).

Apply on Grants.gov →Application closes January 7, 2027

Posted: November 18, 2024
Closes: January 7, 2027
Cost sharing: No
Instrument: Grant
Assistance listing: 93.393
Category: Education, Health
Archives: February 12, 2027

Program funding history

Awards made under Assistance Listing 93.393 across FY2025–FY2027, from public federal spending records.

FY2025 obligated: $803.1M
FY2026 obligated: $769.4M
FY2027 (to date) obligated: $0
Awards in window: 2,546

Top recipients: The Univeristy of Texas M.d. Anderson Cancer Center, Dana-farber Cancer Institute, Inc., Sloan-kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York, University of North Carolina at Chapel Hill

Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →

Synopsis

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

Who can apply

Special district governments
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Native American tribal organizations (other than Federally recognized tribal governments)
Native American tribal governments (Federally recognized)
Independent school districts
City or township governments
County governments
State governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Private institutions of higher education
Public and State controlled institutions of higher education
Public housing authorities/Indian housing authorities
For profit organizations other than small businesses
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

How to apply

Applications go through the official government listing. Grants Radar links you straight to the source — applying is free.

View on Grants.gov Full announcement

Agency contact: National Institutes of Health · [email protected] · 301-402-2541

New to federal funding? How to read an announcement · Who can apply · How grants work

Remind me before this closes

One email about a week before this grant closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.

Stored once per grant, used only for this watch’s emails; every one carries a one-click unsubscribe. Privacy

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.

No spam, ever. Privacy

Similar grants

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
PAR-25-070 · National Institutes of Health · closes January 7, 2027
Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
PAR-25-043 · National Institutes of Health · closes January 7, 2028
Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
PAR-25-044 · National Institutes of Health · closes January 7, 2028
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
PAR-25-096 · National Institutes of Health · closes November 17, 2026
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
PAR-25-095 · National Institutes of Health · closes November 6, 2026
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
PAR-25-167 · National Institutes of Health · closes January 7, 2027

Same-day alerts, matched to you

The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.

Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.

See pricing